Osmotic demyelination syndrome: Difference between revisions

Line 12: Line 12:
*[[Malnutrition]]
*[[Malnutrition]]
*Treatment with vasopressin antagonists (e.g. tolvaptan)
*Treatment with vasopressin antagonists (e.g. tolvaptan)
===Risk Factors for Over-correction<ref>George, J. C., Zafar, W., Bucaloiu, I. D., & Chang, A. R. (2018). Risk Factors and Outcomes of Rapid Correction of Severe Hyponatremia. Clinical Journal of the American Society of Nephrology: CJASN, 13(7), 984–992.</ref>===
*Lower initial sodium
*Schizophrenia
*Lower baseline urine sodium


==Clinical Features==
==Clinical Features==

Revision as of 17:39, 11 August 2018

Background

  • Formerly called "central pontine myelinolysis"
  • A neurologic condition caused by rapid correction of hyponatremia, with starting serum sodium normally 120 meq/L or less
  • Caused by rapid correction of hyponatremia (>12 mEq/L/24 h), as water moves from cells to extracellular fluid, yielding intracellular dehydration.
  • Symptoms are often irreversible or only partially reversible

Risk Factors

Risk Factors for Over-correction[1]

  • Lower initial sodium
  • Schizophrenia
  • Lower baseline urine sodium

Clinical Features

Symptoms can be present 2-6 days after rapid correction of serum sodium

Differential Diagnosis

Altered mental status

Diffuse brain dysfunction

Primary CNS disease or trauma

Psychiatric

Evaluation

  • MRI can be used to visualize the pontine lesion, with a characteristic "batwing" lesion of the pons appearing in typical cases

Management

Disposition

  • Admit

Prevention

See hyponatremia for safe correction rate

See Also

References

  1. George, J. C., Zafar, W., Bucaloiu, I. D., & Chang, A. R. (2018). Risk Factors and Outcomes of Rapid Correction of Severe Hyponatremia. Clinical Journal of the American Society of Nephrology: CJASN, 13(7), 984–992.